ロード中...
Cost per responder of TNF-α therapies in Germany
Tumor necrosis factor α (TNF-α) inhibitors ranked highest in German pharmaceutical expenditure in 2011. Their most important application is the treatment of rheumatoid arthritis (RA). Our objective is to analyze cost per responder of TNF-α inhibitors for RA from the German Statutory Health Insurance...
保存先:
| 出版年: | Clin Rheumatol |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer London
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4544564/ https://ncbi.nlm.nih.gov/pubmed/23877487 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10067-013-2332-1 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|